Diagnosis of infection of implantable central venous catheters by [18F]fluorodeoxyglucose positron emission tomography

被引:35
作者
Miceli, MH
Jackson, LBJ
Walker, RC
Talamo, G
Barlogie, B
Anaissie, EJ
机构
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
[2] Dept Radiol, Little Rock, AR USA
关键词
implantable central venous catheter; infection; FDG PET;
D O I
10.1097/01.mnm.0000130247.37315.66
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective The aim of this study was to evaluate the role of [F-18]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in the diagnosis of infection of implantable vascular catheters. Methods We evaluated six patients with haematological cancer and infection of their implantable vascular catheter and who underwent FDG PET imaging around the time of their infection. Results Six patients with multiple myeloma who developed infection of their implantable device (five port pocket infections and one tunnel infection) were identified. FDG PET revealed increased uptake at the site of the implantable catheter (SUV 2.7-4.5) in all six patients, even in the absence of signs or symptoms of infection at the site of the device (three), and the presence of severe neutropenia (four). The three patients who did not have local inflammation at the site of the device were profoundly neutropenic. The FDG PET diagnosis led to removal of the device in two patients. Conclusion FDG PET is a safe, rapid and accurate tool for diagnosing infection of an implantable catheter, including among those patients not exhibiting local signs and symptoms of infection, and in whom the diagnosis of infected device may be difficult. FDG PET may help prevent the unnecessary removal of implantable intravascular catheters and the unwarranted use of antibiotics. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:813 / 818
页数:6
相关论文
共 21 条
[1]   Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology [J].
Antoch, G ;
Vogt, FM ;
Freudenberg, LS ;
Nazaradeh, F ;
Goehde, SC ;
Barkhausen, J ;
Dahmen, G ;
Bockisch, A ;
Debatin, JF ;
Ruehm, SG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (24) :3199-3206
[2]  
Barnes JR, 1996, AM SURGEON, V62, P203
[3]   Totally implantable central venous access ports for long-term chemotherapy - A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days [J].
Biffi, R ;
de Braud, E ;
Orsi, E ;
Pozzi, S ;
Mauri, S ;
Goldhirsch, A ;
Nole, F ;
Andreoni, B .
ANNALS OF ONCOLOGY, 1998, 9 (07) :767-773
[4]   Drug-induced myelosuppression - Diagnosis and management [J].
Carey, PJ .
DRUG SAFETY, 2003, 26 (10) :691-706
[5]   Diagnosis of venous access port-related infections [J].
Douard, MC ;
Arlet, G ;
Longuet, P ;
Troje, C ;
Rouveau, M ;
Ponscarme, D ;
Eurin, B .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (05) :1197-1202
[6]  
Gibel LJ, 1998, PERITON DIALYSIS INT, V18, P234
[7]  
Hamilton H, 1998, Br J Nurs, V7, P451
[8]  
HAMILTON H, 1998, BR J NURS, V7, P456
[9]   2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer [J].
Hughes, WT ;
Armstrong, D ;
Bodey, GP ;
Bow, EJ ;
Brown, AE ;
Calandra, T ;
Feld, R ;
Pizzo, PA ;
Rolston, KVI ;
Shenep, JL ;
Young, LS .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (06) :730-751
[10]   Venous access port-related bacteremia in patients with acquired immunodeficiency syndrome or cancer: The reservoir as a diagnostic and therapeutic tool [J].
Longuet, P ;
Douard, MC ;
Arlet, G ;
Molina, JM ;
Benoit, C ;
Leport, C .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (12) :1776-1783